Vancouver, British Columbia / November 9th, 2018 – Tabu Equity Investments Inc. (the “Company”) is pleased to announce that it has appointed Joe (Huang) Wong to head up its development team in Asia. Joe will be responsible for the development of new business relationships in Asia, as well as being the representative of Tabu to investment funds and private equity in Hong Kong, China and South East Asia. As part of the arrangement, Joe is coming on as a Tabu board member as the company continues to build out its team.

Mr. Huang (Wong) started his career in the financial sector during the booming decades (1980-90s) in Hong Kong. He later joined his family-owned business, working closely with partners throughout Asia. Mr. Huang successfully acquired a US automotive oil business in the mid-2000s. He quickly expanded the business across Asia and achieved double-digit growth for five consecutive years. Since then, Mr. Huang has further expanded his business into the automotive, transportation, and mining industries.

His business now covers new and revolutionary products including the introduction of proprietary nanotechnology fuel additives. Building on his success and leveraging his contacts across the globe, Mr. Huang has more recently turned his focus to the cannabis industry with a “Farm to Pharma” business model. His business aspirations include cloning, tissue culture, R&D, finished products, and bulk trading in the world’s cannabis market. Tabu is honoured to have Joe as part of the team.

Milton Chen Ph.D – R&D Product Development Asia

Mr. Chen is a biochemical engineer and a subject matter expert in process and product development for active ingredients, oral or sterile dosage drugs, and nutraceuticals.Mr. Chen earned his PhD degree in 1992 and held a certification in Project Management Professional (PMP) since 2010. He has practiced GMP, NHP, and cGMP standard in Canada, Taiwan, and China for more than 20 years. Prior to his recent consulting service, Mr. Chen has spent 15 years in developing the generic cancer drug paclitaxel, brand name TAXOL, from pacific yew tree bark via extraction and purification.Mr. Chen will be responsible for the processing of cannabis plants and the optimal use of biomass with the regulatory compliance in US and Canada. Milton received his B.Sc in Chemical Engineering from the National University of Cheng Kung and his Ph.D in Biochemical Engineering from the University of Queensland in Australia.

Martin (Tianshan) Wang Ph.D – R&D Product Development Asia

Martin has over 20 years experience in pharmaceutical analysis and marker compound analysis of botanical and herbal ingredients. He has a great deal of experience and knowledge regarding the formulation development for botanical drug submissions, natural health and nutraceutical product development. Martin is expert in all unit manufacturing operations for oral dosage forms such as tablets, capsules, soft gels and granules. Martin is also qualified and experienced to work in several forms of pharmaceutical analysis, such as Quantitative Deterioration, Chromatographic Fingerprinting Profile Analysis. Martin received his Ph.D in Natural Products Chemistry from Nanjing University in China, as well as his M.Sc in Pharmacology from the same University.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Tabu’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, aware” and similar expressions, are forward-looking statements.